Marc van Dijk

Founder and owner of the company.

Access Manager for all products for Eastern Europe and Russia. The role was to optimize and/or ensure profitable access for all in-line and pre-launch products within the countries by driving and/or supporting country access-strategies and –initiatives. Market access is defined as discovering and addressing all possible hurdles between patients who are in need of Pfizer products and them actually using Pfizer products. These include hurdles in financing, knowledge, promotion and product availability.

The focus of this role was to be a consultant for the region to promite access by helping to construct the arguments for different stakeholders and provide the data / evidence to support these. This involved close liason with country colleagues, networks of clinical and public health experts and advocacy groups to identify key challenges and opportunities to access for in-line and late stage development drugs.

Responsibility for CNS compounds phase I to IV. Main activities were three-fold: 1) supporting product strategy for the Sales & Marketing and R&D departments by embracing an evidence based “value” concept in it’s broadest sense (ie. optimizing product potential by a process of matching product profile with market needs) and 2) providing drug related outcomes data to demonstrate product value and 3) advice senior managment on a price range drugs in development.

Leading projects to generate price/value statements and to assist in clinical trial design, investment decisions, product pricing, reimbursement negotiations, formulary inclusion and the process of product commercialization. Projects completed were in various disease areas in the US, UK, Brazil, Germany, Italy, the Netherlands, Belgium, Egypt and Malaysia. The projects involved close co operation with various departments of pharmaceutical companies, providers, payers and patient advocacy groups.

Responsible for coordination, initiation and monitoring of phase I, II and III clinical trials. Received FDA/ECGCP, ICH and SOP training. The job involved 40% travel. Experience included designing tracking systems, performing site selection and monitoring visits at hospitals in Belgium and Holland, discussing clinical trial procedures with physicians and nurses and training new recruits for cardiovascular and neurology studies.

Activities included market research, analysis, setting and implementing new strategies for the company in Europe. One of these was starting up and managing a new European business unit for biotechnology research tools. The responsibilities in sales resulted in a close co operation with multiple stakeholders (R&D, regulatory, production, purchasing, logistics) in pharmaceutical and diagnostics companies whereby current and new raw materials were fully adapted to customer requirements.

Molecular Biology